This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

Treatment of HCL with purine analogues (cladribine or pentostatin) has demonstrated high rates of complete response (>75%) and prolongation of disease-free survival. However, relapse is reported in approximately 50% of patients in long-term studies. (1)

The promises of new therapies suggest that most patients can now expect to survive for more than 10 years. With previous methods, median survival was 6 years, with only one-third of patients surviving longer than 10 years. (2)

Reference

  1. Else M, Dearden CE, Catovsky D. Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015 Dec;28(4):217-29.
  2. Paillassa J, Cornet E, Noel S, et al. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer J. 2020 May 27;10(5):62.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.